IL153505A0 - Dds compound and process for the preparation thereof - Google Patents

Dds compound and process for the preparation thereof

Info

Publication number
IL153505A0
IL153505A0 IL15350501A IL15350501A IL153505A0 IL 153505 A0 IL153505 A0 IL 153505A0 IL 15350501 A IL15350501 A IL 15350501A IL 15350501 A IL15350501 A IL 15350501A IL 153505 A0 IL153505 A0 IL 153505A0
Authority
IL
Israel
Prior art keywords
preparation
dds compound
dds
compound
Prior art date
Application number
IL15350501A
Other languages
English (en)
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of IL153505A0 publication Critical patent/IL153505A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL15350501A 2000-06-29 2001-06-27 Dds compound and process for the preparation thereof IL153505A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000195919 2000-06-29
PCT/JP2001/005498 WO2002000734A1 (fr) 2000-06-29 2001-06-27 Compose dds et son procede de preparation

Publications (1)

Publication Number Publication Date
IL153505A0 true IL153505A0 (en) 2003-07-06

Family

ID=18694503

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15350501A IL153505A0 (en) 2000-06-29 2001-06-27 Dds compound and process for the preparation thereof

Country Status (12)

Country Link
US (1) US20030166513A1 (zh)
EP (1) EP1298145A4 (zh)
KR (1) KR20030031502A (zh)
CN (1) CN1449412A (zh)
AU (1) AU2001267831A1 (zh)
BR (1) BR0112287A (zh)
CA (1) CA2412582A1 (zh)
IL (1) IL153505A0 (zh)
MX (1) MXPA02012791A (zh)
NO (1) NO20026212L (zh)
WO (1) WO2002000734A1 (zh)
ZA (1) ZA200300743B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531572B1 (en) 1994-07-25 2003-03-11 Roche Diagnostics Gmbh Metal chelate-labelled peptides
PL221351B1 (pl) 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych
DK2907824T3 (en) * 2012-10-11 2018-07-23 Daiichi Sankyo Co Ltd ANTIBODY-drug conjugate
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
SI3088419T1 (sl) 2013-12-25 2019-01-31 Daiichi Sankyo Company Zdravilni konjugat anti trop2 protitelesa
DK3466976T3 (da) 2014-01-31 2021-12-13 Daiichi Sankyo Co Ltd Anti-her2-antistof-lægemiddelkonjugat
JP2017114763A (ja) * 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
KR102351755B1 (ko) 2014-04-10 2022-01-14 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
ES2754348T3 (es) * 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
AU2016286898B2 (en) 2015-06-29 2022-12-08 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
FR3045608A1 (fr) * 2015-12-18 2017-06-23 Rhodia Operations Dextrane carboxyle
WO2018110515A1 (ja) 2016-12-12 2018-06-21 第一三共株式会社 抗体－薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
KR102537651B1 (ko) 2017-01-17 2023-05-26 다이이찌 산쿄 가부시키가이샤 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
CA3073924C (en) 2017-08-31 2023-10-17 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
BR112020003466B1 (pt) 2017-08-31 2023-12-12 Daiichi Sankyo Company, Limited Métodos de produção de composto, e, composto
JP2021524740A (ja) 2018-05-18 2021-09-16 グリコトープ ゲーエムベーハー 抗ｍｕｃ１抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134348C (en) * 1993-02-26 2007-01-02 Hideo Nogusa Polysaccharide derivatives and drug carriers
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
TW409058B (en) * 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CN1250293C (zh) * 1998-05-22 2006-04-12 第一制药株式会社 药物复合物
BR9915198A (pt) * 1998-10-30 2001-08-14 Daiichi Seiyaku Co Composto dds e método para medição do mesmo
EP1308171A1 (en) * 2000-07-13 2003-05-07 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds

Also Published As

Publication number Publication date
EP1298145A4 (en) 2004-12-08
MXPA02012791A (es) 2003-12-11
ZA200300743B (en) 2004-02-10
CA2412582A1 (en) 2002-01-03
KR20030031502A (ko) 2003-04-21
CN1449412A (zh) 2003-10-15
US20030166513A1 (en) 2003-09-04
AU2001267831A1 (en) 2002-01-08
NO20026212L (no) 2003-02-06
EP1298145A1 (en) 2003-04-02
WO2002000734A1 (fr) 2002-01-03
NO20026212D0 (no) 2002-12-23
BR0112287A (pt) 2003-05-06

Similar Documents

Publication Publication Date Title
HK1044338A1 (en) 5-Pyridyl-1, 3-azole compounds, process for producing the same and use thereof
HK1060305A1 (en) Contraception process and administration form for the same
PL361234A1 (en) Aqueous formulations and process for preparing the same
IL153505A0 (en) Dds compound and process for the preparation thereof
IL187126A0 (en) Process for the preparation of 4 - haloalkylnicotinonitriles
IL145520A0 (en) Flame-retarding composition and process for the preparation thereof
EP0990632A4 (en) ADAMANTANEMETHANOL DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF
IL139023A0 (en) Process for the preparation of 2,3,5-trimethyl-p- benzoquinone
HUP0401577A3 (en) Process for the preparation of 2,4-didezoxyhexoses and 2,4,6-tridezoxyhexoses
AU8824201A (en) Process for the preparation of dinapsoline
IL190807A0 (en) Process for the preparation of 2-aminoethylpyridines
EG22846A (en) Process for the preparation of urea
IL150897A0 (en) Process for the preparation of acetyl-amidiniophenylalanyl cyclohexylglycyl-pyridinioalaninamides
IL138691A (en) Process for the preparation of 3-acyl-indoles
HUP0202865A3 (en) Process for the preparation of 2-cyanopyridines
HUP0105166A3 (en) Substances wk-5344a and wk-5344b and process for producing the same
IL137364A (en) Process for the preparation of 6,6-dimethylhept-1-en-4-yn-3-ol
EG22758A (en) Process for the preparation of urea
EP1299396A4 (en) NOVEL CEPHALOSPORIN COMPOUNDS AND PROCESSES FOR THE PREPARATION THEREOF
GB0012249D0 (en) Process for the preparation of 11-oxaprostaglandins
AU2002221114A1 (en) Novel ss-lactam compounds and process for preparing the same
HRP20020098A2 (en) Process for the preparation of isotretinoin
AU2001256774A1 (en) Thiazolylethanone compounds and process for the preparation thereof
EP1294730A4 (en) NEW CEPHALOSPORINE COMPOUNDS AND A METHOD FOR PRODUCING THE SAME
HU0003616D0 (en) Process for the preparation of pyridyl-ketone